StreetInsider.com News Articles

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

NEW YORK, July 30, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, LLP advised Ashlins Ocular Pharmaceuticals, Inc. (Ashlins), a wholly owned subsidiary of Ashlins Pharmaceuticals, on its exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950) (Lee's Pharm), a publicly listed biopharmaceutical company.

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Greenberg Traurig Represents Ashlins Pharmaceuticals in Strategic Global Life Sciences Licensing Transaction

Thu, 30 Jul 2026 16:00:00 -0400

Ashlins, Lee's Pharm strike license deal worth up to $31M

Tue, 21 Jul 2026 07:00:24 -0400

Ashlins Pharmaceuticals announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee's Pharmaceutical Holdings Limited (HKEX: 0950).

Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize drug products incorporating Lee's Pharm's interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau, and Taiwan.

Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.

Interferon alpha-2b is a recombinant human type I interferon used as the active substance

Ashlins, Lee's Pharm strike license deal worth up to $31M

Tue, 21 Jul 2026 07:00:24 -0400

Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.

Interferon alpha-2b is a recombinant human type I interferon used as the active substance

Ashlins, Lee's Pharm strike license deal worth up to $31M

Tue, 21 Jul 2026 07:00:24 -0400

Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.

Interferon alpha-2b is a recombinant human type I interferon used as the active substance

Ashlins, Lee's Pharm strike license deal worth up to $31M

Tue, 21 Jul 2026 07:00:24 -0400

Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.

Interferon alpha-2b is a recombinant human type I interferon used as the active substance

Ashlins, Lee's Pharm strike license deal worth up to $31M

Tue, 21 Jul 2026 07:00:24 -0400

Lee's Pharm will supply the API and is eligible to receive up to $31 million in upfront, development, and annual commercial milestone payments, subject to specified conditions.

Interferon alpha-2b is a recombinant human type I interferon used as the active substance

Ashlins Pharmaceuticals and Lee's Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million

Tue, 21 Jul 2026 07:00:00 -0400

Lee’s is eligible to receive up to $31 million in upfront and milestone payments.

NEW YORK--(BUSINESS WIRE)-- Ashlins Pharmaceuticals today announced that its wholly owned subsidiary, Ashlins Ocular Pharmaceuticals, Inc., has entered into an exclusive license and supply agreement with Lee’s Pharmaceutical Holdings Limited (HKEX: 0950), a publicly listed biopharmaceutical company with more than 30 years of industry experience.

Under the agreement, Ashlins has obtained exclusive rights to develop and commercialize certain drug products incorporating Lee’s Pharm’s interferon alpha-2b active pharmaceutical ingredient (API) in all territories outside Mainland China, Hong Kong, Macau and Taiwan. Lee’s Pharm will supply the

Ashlins Pharmaceuticals and Lee's Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million

Tue, 21 Jul 2026 07:00:00 -0400

Lee’s is eligible to receive up to $31 million in upfront and milestone payments.

Ashlins Pharmaceuticals and Lee's Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million

Tue, 21 Jul 2026 07:00:00 -0400

Lee’s is eligible to receive up to $31 million in upfront and milestone payments.

Ashlins Pharmaceuticals and Lee's Pharm Announce Exclusive License and Supply Agreement Valued at Up to $31 Million

Tue, 21 Jul 2026 07:00:00 -0400

Lee’s is eligible to receive up to $31 million in upfront and milestone payments.